These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 20490589

  • 1. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis.
    Tanaka H, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito Y, Sato N, Kawasaki Y, Suzuki J.
    Clin Rheumatol; 2010 Sep; 29(9):1049-54. PubMed ID: 20490589
    [Abstract] [Full Text] [Related]

  • 2. Mizoribine for the treatment of lupus nephritis in children and adolescents.
    Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, Ito E, Waga S.
    Clin Nephrol; 2004 Dec; 62(6):412-7. PubMed ID: 15630899
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.
    Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E.
    Pediatr Nephrol; 2006 Jul; 21(7):962-6. PubMed ID: 16773408
    [Abstract] [Full Text] [Related]

  • 5. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.
    Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, Naito M, Koike M, Nitta K, Nihei H.
    Clin Nephrol; 2005 Jul; 64(1):28-34. PubMed ID: 16047642
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the tohoku pediatric study group.
    Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, Kondo Y, Suzuki J.
    Nephron Clin Pract; 2008 Jul; 110(2):c73-9. PubMed ID: 18758186
    [Abstract] [Full Text] [Related]

  • 8. Mizoribine selectively attenuates monocyte chemoattractant protein-1 production in cultured human glomerular mesangial cell: a possible benefit of its use in the treatment of lupus nephritis.
    Aizawa T, Imaizumi T, Tsuruga K, Watanabe S, Chiba Y, Matsumiya T, Yoshida H, Tanaka H.
    Nephrology (Carlton); 2014 Jan; 19(1):47-52. PubMed ID: 24134561
    [Abstract] [Full Text] [Related]

  • 9. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis.
    Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S.
    Clin Nephrol; 2003 Dec; 60(6):390-4. PubMed ID: 14690255
    [Abstract] [Full Text] [Related]

  • 10. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X, Gu F, Chen W, Liu Y, Wei H, Liu L, Yin S, Da Z, Sun L.
    Chin Med J (Engl); 2014 Dec; 127(21):3718-23. PubMed ID: 25382325
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Morphological Indexes: Can They Predict Lupus Nephritis Outcomes? A Retrospective Study.
    Navarro D, Ferreira AC, Viana H, Carvalho F, Nolasco F.
    Acta Med Port; 2019 Oct 01; 32(10):635-640. PubMed ID: 31625875
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.
    Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, Qu Z, Chen MH, Gao JJ, Li ZY, Zheng X, Ao J, Zhu SN, Wang SX, Zhao MH, Zou WZ, Liu G.
    Kidney Int; 2010 May 01; 77(9):820-9. PubMed ID: 20182417
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Predominance of Th1 immune response in diffuse proliferative lupus nephritis.
    Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H.
    Arthritis Rheum; 2001 Sep 01; 44(9):2097-106. PubMed ID: 11592372
    [Abstract] [Full Text] [Related]

  • 17. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients.
    Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E.
    Clin Rheumatol; 2008 Jan 01; 27(1):85-9. PubMed ID: 17483980
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mizoribine therapy in a patient with lupus nephritis: the association between mizoribine concentration and peritoneal dialysis.
    Kuroda T, Kobayashi D, Sato H, Oyanagi A, Wada Y, Murakami S, Nakano M, Narita I.
    Mod Rheumatol; 2010 Jun 01; 20(3):296-300. PubMed ID: 20082109
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathologic correlations in lupus nephritis in Lima, Peru.
    Hurtado A, Asato C, Escudero E, Stromquist CS, Urcia J, Hurtado ME, de La Cruz S, Wener MH, Zavala R, Johnson RJ.
    Nephron; 1999 Jun 01; 83(4):323-30. PubMed ID: 10575294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.